AstraZeneca's Evusheld Covid-19 Preventative Drug Approved in EU
28 März 2022 - 8:54AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Monday that its Evusheld long-acting
antibody combination has been approved in the European Union for
the prevention of the coronavirus in a broad population.
The pharmaceutical major said a Phase 3 trial has been showing
that the treatment--a combination of antibodies tixagevimab and
cilgavimab--significantly reduces the risk of developing
symptomatic Covid-19 with protection lasting at least six
months.
The data from the trial showed Evusheld reduced the risk of
developing symptomatic Covid-19 by 77% compared with a placebo
initially, and an 83% reduction at the six-month mark, the company
said. The treatment also retains its neutralizing activity against
the Omicron BA.2 subvariant, which is now the dominant strain in
Europe.
Evusheld is already authorized for emergency use in the U.S. and
has been granted conditional marketing authorization in the U.K.
The company said the treatment would be particularly beneficial for
those not adequately protected by a coronavirus vaccine, such as
the immunocompromised.
"The EU approval represents an important milestone in our
efforts to help prevent Covid-19, and we will continue to work with
governments across Europe to make Evusheld available as quickly as
possible," Mene Pangalos, executive vice president of
biopharmaceuticals research and development, said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 28, 2022 02:39 ET (06:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
